LAUSANNE, Switzerland & SAN DIEGO–(BUSINESS WIRE)– #Cardiology–HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Trial of HTX-001, an Investigational Cellular Reprogramming Therapy for Cardiac Fibrosis
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
